Beating the odds: BETs in disease

Trends in Biochemical Sciences

Volumn 40, Issue 8, 2015, Pages 468-479

  Wang, Chen Yi ^a   Filippakopoulos, Panagis ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

BETs; Cancer; Inflammation; Small molecule inhibitor; Transcription; Viral infection

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; APABETALONE; AZACITIDINE; BAY 1238097; BROMO AND EXTRATERMINAL PROTEIN; BROMO AND EXTRATERMINAL PROTEIN INHIBITOR; BROMODOMAIN 2 PROTEIN; BROMODOMAIN 3 PROTEIN; BROMODOMAIN 4 PROTEIN; BROMODOMAIN PROTEIN; CPI 0610; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FEDRATINIB; GK 525762; GLYCOPROTEIN E1; GLYCOPROTEIN E2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; OXT 015; PHOSPHOTRANSFERASE INHIBITOR; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN INHIBITOR; RVX 000222; TEN 010; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR TWIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NONHISTONE PROTEIN;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ATHEROSCLEROSIS; BET GENE; CARBOXY TERMINAL SEQUENCE; CARCINOMA; CASTRATION RESISTANT PROSTATE CANCER; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIACETYLATION; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; EPSTEIN BARR VIRUS; ERYTHROPOIESIS; GENE REPRESSION; GENETIC CONSERVATION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HIV GENE; HUMAN; HUMAN HERPESVIRUS 8; HYDROPHOBICITY; INFLAMMATION; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MERKEL CELL POLYOMAVIRUS; MIDLINE CARCINOMA; MULTIPLE MYELOMA; MURINE LEUKEMIA VIRUS; MYELODYSPLASTIC SYNDROME; MYELOMA; MYELOPROLIFERATIVE NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; SPERMATOGENESIS; TRANSCRIPTION REGULATION; TREATMENT INDICATION; TRIPLE NEGATIVE BREAST CANCER; VIRUS GENE; VIRUS GENOME; WART VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DISEASES; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE;

MURINAE;

ANIMALS; CHROMOSOMAL PROTEINS, NON-HISTONE; DISEASE; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION, GENETIC;

EID: 84937525036     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.06.002     Document Type: Review

References (118)

1. Filippakopoulos P., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149:214-231.
2. Filippakopoulos P., Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 2014, 13:337-356.
3. Fukazawa H., Masumi A. The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal. Biol. Pharm. Bull. 2012, 35:2064-2068.
4. Garcia-Gutierrez P., et al. Association of bromodomain BET proteins with chromatin requires dimerization through the conserved motif B. J. Cell Sci. 2012, 125:3671-3680.
5. Lin Y.J., et al. Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4. Protein Sci. 2008, 17:2174-2179.
6. Rahman S., et al. The Brd4 extraterminal domain confers transcription activation independent of PTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 2011, 31:2641-2652.
7. Abbate E.A., et al. Structure of the papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates HPV chromosomal association. Mol. Cell 2006, 24:877-889.
8. Nakamura Y., et al. Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4. J. Biol. Chem. 2007, 282:4193-4201.
9. Moriniere J., et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009, 461:664-668.
10. Umehara T., et al. Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain. J. Biol. Chem. 2010, 285:7610-7618.
11. Matzuk M.M., et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012, 150:673-684.
12. Vollmuth F., Geyer M. Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains. Angew. Chem. Int. Ed. Engl. 2010, 49:6768-6772.
13. Huang B., et al. Brd4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA. Mol. Cell. Biol. 2009, 29:1375-1387.
14. Gamsjaeger R., et al. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol. Cell. Biol. 2011, 31:2632-2640.
15. Lamonica J.M., et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E159-E168.
16. Shi J., et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 2014, 25:210-225.
17. Borcherding N., et al. Paracrine WNT5A signaling inhibits expansion of tumor-initiating cells. Cancer Res. 2015, 75:1972-1982.
18. Schroder S., et al. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J. Biol. Chem. 2012, 287:1090-1099.
19. You J., et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J. Virol. 2006, 80:8909-8919.
20. Hellert J., et al. A structural basis for BRD2/4-mediated host chromatin interaction and oligomer assembly of Kaposi sarcoma-associated herpesvirus and murine gammaherpesvirus LANA proteins. PLoS Pathog. 2013, 9:e1003640.
21. You J., et al. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004, 117:349-360.
22. Smith J.A., et al. Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3752-3757.
23. Wu S.Y., et al. Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev. 2006, 20:2383-2396.
24. Chang S.W., et al. Phosphorylation of HPV-16 E2 at serine 243 enables binding to Brd4 and mitotic chromosomes. PLoS ONE 2014, 9:e110882.
25. Itzen F., et al. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res. 2014, 42:7577-7590.
26. Helfer C.M., et al. The cellular bromodomain protein Brd4 has multiple functions in E2-mediated papillomavirus transcription activation. Viruses 2014, 6:3228-3249.
27. Yan J., et al. Abrogation of the Brd4-positive transcription elongation factor B complex by papillomavirus E2 protein contributes to viral oncogene repression. J. Virol. 2010, 84:76-87.
28. Tsume M., et al. Brd2 is required for cell cycle exit and neuronal differentiation through the E2F1 pathway in mouse neuroepithelial cells. Biochem. Biophys. Res. Commun. 2012, 425:762-768.
29. Belkina A.C., et al. The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis. J. Leukoc. Biol. 2014, 95:451-460.
30. Hnilicova J., et al. The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing. Mol. Biol. Cell 2013, 24:3557-3568.
31. Stonestrom A.J., et al. Functions of BET proteins in erythroid gene expression. Blood 2015, 125:2825-2834.
32. Jang M.K., et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
33. Yang Z., et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19:535-545.
34. Gaucher J., et al. Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J. 2012, 31:3809-3820.
35. + T cells. J. Biol. Chem. 2012, 287:43137-43155.
36. Liu W., et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013, 155:1581-1595.
37. Kanno T., et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol. 2014, 21:1047-1057.
38. Dey A., et al. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol. Biol. Cell 2009, 20:4899-4909.
39. Zhao R., et al. Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation. Nat. Cell Biol. 2011, 13:1295-1304.
40. Wang R., et al. Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J. Biol. Chem. 2012, 287:10738-10752.
41. Floyd S.R., et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 2013, 498:246-250.
42. Pivot-Pajot C., et al. Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol. Cell. Biol. 2003, 23:5354-5365.
43. Berkovits B.D., Wolgemuth D.J. The first bromodomain of the testis-specific double bromodomain protein Brdt is required for chromocenter organization that is modulated by genetic background. Dev. Biol. 2011, 360:358-368.
44. Belkina A.C., Denis G.V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 2012, 12:465-477.
45. Lee Y.S., et al. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 2013, 24:603-616.
46. French C. NUT midline carcinoma. Nat. Rev. Cancer 2014, 14:149-150.
47. Reynoird N., et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010, 29:2943-2952.
48. Schwartz B.E., et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011, 71:2686-2696.
49. Wang R., You J. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation. J. Biol. Chem. 2015, 290:2744-2758.
50. Grayson A.R., et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 2014, 33:1736-1742.
51. Delmore J.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
52. Chaidos A., et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2014, 123:697-705.
53. Mertz J.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16669-16674.
54. Dawson M.A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
55. Zuber J., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
56. Herrmann H., et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 2012, 3:1588-1599.
57. Fiskus W., et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol. Cancer Ther. 2014, 13:1142-1154.
58. Picaud S., et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res. 2013, 73:3336-3346.
59. Ott C.J., et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
60. Da Costa D., et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013, 3:e126.
61. Roderick J.E., et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 2014, 123:1040-1050.
62. Tan Y., et al. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer Biol. Ther. 2015, 16:580-588.
63. Henssen A., et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 2013, 4:2080-2095.
64. Bandopadhayay P., et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin. Cancer Res. 2014, 20:912-925.
65. Venkataraman S., et al. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget 2014, 5:2355-2371.
66. Rajagopalan V., et al. Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing. Cell. Mol. Neurobiol. 2014, 34:1059-1069.
67. Gao L., et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS ONE 2013, 8:e63563.
68. Asangani I.A., et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014, 510:278-282.
69. Cho H., et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 2014, 4:318-333.
70. Tsai L.H., et al. The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss. Oncogene 2015, 34:1641-1649.
71. Shimamura T., et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 2013, 19:6183-6192.
72. Baratta M.G., et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:232-237.
73. Qiu H., et al. JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. Oncotarget 2015, 6:6915-6930.
74. Segura M.F., et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013, 73:6264-6276.
75. Shao Q., et al. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Cancer Res. 2014, 74:7090-7102.
76. + breast cancers. Oncotarget 2015, 6:2407-2420.
77. Puissant A., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3:308-323.
78. Wyce A., et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 2013, 8:e72967.
79. Shahbazi J., et al. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget 2014, 5:4257-4268.
80. Althoff K., et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene 2014, Published online September 1, 2014. 10.1038/onc.2014.269.
81. Fowler T., et al. Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. PLoS ONE 2014, 9:e87003.
82. Kumar K., et al. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci. Rep. 2015, 5:9489.
83. Hnisz D., et al. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
84. Mansour M.R., et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 2014, 346:1373-1377.
85. Loven J., et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
86. Zou Z., et al. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene 2014, 33:2395-2404.
87. Kaikkonen M.U., et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 2013, 51:310-325.
88. Brown J.D., et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 2014, 56:219-231.
89. Hah N., et al. Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:E297-E302.
90. Anand P., et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013, 154:569-582.
91. Sakakibara N., et al. Brd4 is displaced from HPV replication factories as they expand and amplify viral DNA. PLoS Pathog. 2013, 9:e1003777.
92. Li J., et al. Brd4-mediated nuclear retention of the papillomavirus E2 protein contributes to its stabilization in host cells. Viruses 2014, 6:319-335.
93. Zhou H., et al. Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe 2015, 17:205-216.
94. Boehm D., et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2013, 12:452-462.
95. Li Z., et al. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 2013, 41:277-287.
96. Zhu J., et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep. 2012, 2:807-816.
97. Emadali A., et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol. Med. 2013, 5:1180-1195.
98. Feng Q., et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014, 24:809-819.
99. Loosveld M., et al. Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. Oncotarget 2014, 5:3168-3172.
100. Pastori C., et al. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics 2014, 9:611-620.
101. Wong C., et al. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis. 2014, 5:e1450.
102. Wang F., et al. Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem. J. 2010, 425:71-83.
103. Chachua T., et al. Sex-specific behavioral traits in the Brd2 mouse model of juvenile myoclonic epilepsy. Genes Brain Behav. 2014, 13:702-712.
104. Yavuz E.N., et al. Bromodomain-containing protein 2 gene in photosensitive epilepsy. Seizure 2012, 21:646-648.
105. Boi M., et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin. Cancer Res. 2015, 21:1628-1638.
106. Di Micco R., et al. Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep. 2014, 9:234-247.
107. Bolden J.E., et al. Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Cell Rep. 2014, 8:1919-1929.
108. Wienerroither S., et al. Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. Mol. Cell. Biol. 2014, 34:415-427.
109. Wang F., et al. Brd2 gene disruption causes 'metabolically healthy' obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam. Horm. 2013, 91:49-75.
110. Miyoshi, S. et al. Mitsubishi Tanabe Pharma Corporation. Antitumor agent, WO 2009/084693 A1.
111. Filippakopoulos P., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
112. Nicodeme E., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
113. Ciceri P., et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 2014, 10:305-312.
114. Martin M.P., et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 2013, 8:2360-2365.
115. Dittmann A., et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 2014, 9:495-502.
116. Ember S.W., et al. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 2014, 9:1160-1171.
117. Zippo A., et al. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009, 138:1122-1136.
118. Pott S., Lieb J.D. What are super-enhancers?. Nat Genet. 2015, 47:8-12.